Lyell Immunopharma, Inc. — All Filings
300 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
S-1
S-1/A
S-3
S-3ASR
S-8
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | — | 0001415889-25-005747 | Feb 26, 2025 | Feb 10, 2025 |
| SCHEDULE 13G/A | — | 0001104659-25-013912 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001072613-25-000168 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0002012383-25-001224 | Feb 5, 2025 | — |
| 8-K | 8-K | 0001193125-25-012249 | Jan 24, 2025 | Jan 23, 2025 |
| 8-K/A | 8-K/A | 0001628280-25-001065 | Jan 10, 2025 | Oct 31, 2024 |
| 8-K | 8-K | 0001193125-24-273688 | Dec 10, 2024 | Dec 9, 2024 |
| 424B5 | 424B5 | 0001193125-24-272943 | Dec 9, 2024 | — |
| EFFECT | — | 9999999995-24-003682 | Dec 5, 2024 | — |
| CORRESP | — | 0001193125-24-269995 | Dec 3, 2024 | — |
| UPLOAD | — | 0000000000-24-013301 | Dec 3, 2024 | — |
| S-3 | S-3 | 0001193125-24-268106 | Nov 29, 2024 | — |
| 8-K | 8-K | 0001193125-24-266101 | Nov 26, 2024 | Nov 22, 2024 |
| SC 13G/A | — | 0000932471-24-001105 | Nov 12, 2024 | — |
| 8-K | 8-K | 0001628280-24-046254 | Nov 7, 2024 | — |
| 10-Q | 10-Q | 0001628280-24-046285 | Nov 7, 2024 | Sep 30, 2024 |
| SC 13G/A | — | 0000932471-24-000620 | Nov 4, 2024 | — |
| 3 | — | 0001415889-24-025909 | Nov 1, 2024 | Oct 31, 2024 |
| 4 | — | 0001415889-24-025912 | Nov 1, 2024 | Oct 31, 2024 |
| 8-K | 8-K | 0001193125-24-248760 | Oct 31, 2024 | — |
| SC 13G | SC 13G | 0001104659-24-113135 | Oct 31, 2024 | — |
| 8-K | 8-K | 0001193125-24-242808 | Oct 24, 2024 | — |
| 8-K | 8-K | 0001628280-24-035603 | Aug 7, 2024 | — |
| 10-Q | 10-Q | 0001628280-24-035617 | Aug 7, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0001193125-24-168597 | Jun 26, 2024 | — |
| 4 | — | 0001415889-24-017183 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017176 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017162 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017152 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017147 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017146 | Jun 17, 2024 | Jun 14, 2024 |
| 4 | — | 0001415889-24-017220 | Jun 17, 2024 | Jun 14, 2024 |
| 8-K | 8-K | 0001193125-24-161601 | Jun 14, 2024 | — |
| 10-Q | 10-Q | 0001628280-24-020467 | May 6, 2024 | Mar 31, 2024 |
| 8-K | 8-K | 0001628280-24-020466 | May 6, 2024 | — |
| 424B5 | 424B5 | 0001193125-24-131492 | May 6, 2024 | — |
| EFFECT | — | 9999999995-24-001369 | May 3, 2024 | — |
| CORRESP | — | 0001193125-24-127548 | May 1, 2024 | — |
| DEFA14A | DEFA14A | 0001140361-24-021011 | Apr 22, 2024 | — |
| DEF 14A | DEF 14A | 0001140361-24-021008 | Apr 22, 2024 | Jun 14, 2023 |
| ARS | ARS | 0001140361-24-021014 | Apr 22, 2024 | Dec 31, 2023 |
| UPLOAD | — | 0000000000-24-002403 | Mar 4, 2024 | — |
| S-3 | S-3 | 0001193125-24-051177 | Feb 29, 2024 | — |
| S-8 | S-8 | 0001193125-24-051169 | Feb 29, 2024 | — |
| 10-K | 10-K | 0001628280-24-007592 | Feb 28, 2024 | Dec 31, 2023 |
| 8-K | 8-K | 0001628280-24-007579 | Feb 28, 2024 | — |
| SC 13G/A | ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G/A(#1) | 0001072613-24-000252 | Feb 14, 2024 | — |
| 4 | FORM 4 SUBMISSION | 0001209191-24-003272 | Feb 13, 2024 | Feb 9, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-003276 | Feb 13, 2024 | Feb 9, 2024 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-003274 | Feb 13, 2024 | Feb 9, 2024 |